AI in Drug Discovery and Clinical Trials Market Size, Share, By Offering [Software (End-to-end Platforms, Analytics Tools, and Others), Services (Consulting, Model Development, and Others), Hardware (Specialized Compute, On-prem Servers, and Others)], Technology (Machine Learning, Deep Learning, Graph ML, Reinforcement Learning, and Others), Clinical Trial Phase (Preclinical, Phase I, Phase II, Phase III, and Phase IV), Data Source (Genomics / Multi-omics, Structural Biology, High-throughput Screening (HTS), Electronic Health Records (EHR), and Others), Therapeutic Area (Oncology, CNS (neurology/psychiatry), Cardiovascular/Metabolic, Infectious Diseases, Rare & Orphan Disease, and Others), Application [Drug discovery (Target Identification & Validation, Virtual Screening & Docking, And Others), Clinical Trials (Protocol Design & Power/Sample-Size Modeling, Patient Identification & Eligibility Screening, and Others)], End User (Large Pharmaceutical Companies, Biotech / Small & Mid Pharma, Contract Research Organizations (CROs), Academic & Translational Research Centers, and Others), and Region - Trends, Analysis, and Forecast till 2035

Report Code: PMI598825 | Publish Date: August 2025 | No. of Pages: 179

Ai In Drug Discovery And Clinical Trials Market Companies

BenevolentAI, Insilico Medicine, BIOXCEL THERAPEUTICS INC., Schrödinger, Inc., Valo Health, and other major firms are involved in the AI in Drug Discovery and Clinical Trials market. Key growth strategies for AI in drug discovery and clinical trials companies include partnerships with pharma and CROs, acquisitions of datasets and AI tools, investments in cutting-edge technologies such as generative AI, offering scalable cloud-based platforms, focusing on high-value therapeutic areas, and strict regulatory compliance to boost adoption and trust.

List of Key Players in the Market:

  • BenevolentAI
  • Insilico Medicine
  • Exscientia plc
  •  Recursion
  •  Schrödinger, Inc.
  •  Valo Health
  • Shenzhen Jingtai Technology Co., Ltd
  • Owkin, Inc
  • BIOXCEL THERAPEUTICS INC.
  • HEALX
  • Gero.ai
  • Verge Analytics, Inc.
  • Syntekabio, Inc.
  • Evaxion A/S
  • Standigm Inc.

Recent News:

  • Isomorphic Labs, a division of Alphabet dedicated to AI medicine research, hopes to start clinical trials for its AI-generated cancer medications, on July 2025. Together with Google DeepMind, Isomorphic created AlphaFold 3, an AI model that can precisely forecast intricate protein shapes and chemical interactions. John Jumper and Demis Hassabis, who were awarded the 2024 Nobel Prize, created AlphaFold.
  • Advarra, the industry leader in clinical research and regulatory review technology, announced the establishment of the Council for Responsible Use of AI in Clinical Trials, on June 2025. In order to promote the use of AI across the clinical trial lifecycle, the Council—which consists of professionals from many industrial sectors—will concentrate on establishing benchmarks, enhancing model governance, and establishing quantifiable results.
  • Utilizing artificial intelligence (AI) to transform drug research, the AI Small Molecule Drug Discovery Center was established by the Icahn School of Medicine at Mount Sinai, on April 2025. To find and create novel small-molecule treatments with previously unheard-of speed and accuracy, the new Center will combine artificial intelligence (AI) with conventional drug development techniques.
  • The debut of its unified platform of SaaS-based products to complement its current portfolio of bespoke solutions and services, Saama is a supplier of AI- and ML-based solutions that speed up clinical development and commercialization, on September 2023. Using its well-proven artificial intelligence (AI) and machine learning (ML) improved solutions, the new Saama platform automates critical clinical development procedures and offers a comprehensive picture of patient progress and trial operations in one place.